Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Clinical and Experimental Metastasis

• Publication date

  1997-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1018454305889PMID 9219730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining

  2007cited by this paper
• Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma

  2004cited by this paper
• Prognostic factors in gastric carcinoma.

  1997cited by this paper
• Prognostic value of the plasminogen activation system in patients with gastric carcinoma

  1996influential reference
• Relationship between expression of plasminogen activator system and metastatic ability in human cancers.

  1996cited by this paper
• Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor‐1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues

  1996cited by this paper
• Cysteine and serine proteases in gastric cancer

  1995cited by this paper
• Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas

  1995cited by this paper
• Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

  1995cited by this paper
• Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

  1995cited by this paper
• Urokinase receptor and colorectal cancer survival.

  1994cited by this paper
• Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

  1994cited by this paper
• Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

  1994cited by this paper
• The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.

  1994cited by this paper
• Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.

  1994cited by this paper
• Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

  1994cited by this paper
• Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

  1994cited by this paper
• Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.

  1994cited by this paper
• Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis

  1994cited by this paper
• Goseki histological grading of gastric cancer is an important predictor of outcome.

  1994cited by this paper
• Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

  1994cited by this paper
• Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.

  1994cited by this paper
• Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?

  1994cited by this paper
• Urokinase receptor and colorectal cancer survival.

  1994cited by this paper
• Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer

  1994cited by this paper
• High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

  1993cited by this paper
• Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

  1993cited by this paper
• Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.

  1993cited by this paper
• Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.

  1993cited by this paper
• Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.

  1993cited by this paper
• Prevention of metastasis by inhibition of the urokinase receptor.

  1993cited by this paper
• Prognostic factors in gastric carcinoma. Results of the German gastric carcinoma study 1992

  1993cited by this paper
• The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer

  1992cited by this paper
• Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.

  1992cited by this paper
• Biology of tumour metastasis.

  1992cited by this paper
• Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

  1992cited by this paper
• Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy

  1992cited by this paper
• Type‐1 plasminogen activator inhibitor in human breast carcinomas

  1992cited by this paper
• In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion

  1991cited by this paper
• Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.

  1991cited by this paper
• Plasminogen activator inhibitor 1 in human carcinoma tissues

  1991cited by this paper
• Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.

  1991cited by this paper
• Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

  1991cited by this paper
• Relationship between plasminogen activators and stomach carcinoma stage.

  1991cited by this paper
• Tumor invasion and metastasis: an imbalance of positive and negative regulation.

  1991cited by this paper
• Plasminogen activators in human gastric cancers : correlation with DNA ploidy and immunohistochemical staining

  1991cited by this paper
• Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

  1991cited by this paper
• Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.

  1991cited by this paper
• Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

  1991cited by this paper
• Differential protease expression by cutaneous squamous and basal cell carcinomas.

  1991cited by this paper
• Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene.

  1990cited by this paper
• The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes

  1990cited by this paper
• Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

  1990cited by this paper
• Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1.

  1990cited by this paper
• Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

  1990cited by this paper
• Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

  1990cited by this paper
• Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants

  1989cited by this paper
• Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.

  1989cited by this paper
• Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

  1988cited by this paper
• Plasminogen activators and plasminogen activator inhibitor in malignant and non‐malignant ascitic fluid

  1988cited by this paper
• The relevance of plasminogen activators to neoplastic growth. A review of recent literature.

  1988cited by this paper
• Cell-associated plasminogen activation: regulation and physiological functions.

  1988cited by this paper
• Tumor invasion: a consequence of destructive and compositional matrix alterations.

  1988cited by this paper
• The urokinase type of plasminogen activator in cancer of digestive tracts.

  1988cited by this paper
• Plasminogen activator inhibitors.

  1987influential reference
• Plasminogen Activator Activity and Composition in Human Colorectal Carcinomas

  1987cited by this paper
• The Most Important Prognostic Factors for Gastric Cancer Patients: A Study Using Univariate and Multivariate Analyses

  1987cited by this paper
• Fibrinolytic Pathways and the Endothelium

  1987cited by this paper
• Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.

  1987cited by this paper
• Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.

  1986cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

  1985cited by this paper
• Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue.

  1984cited by this paper
• Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.

  1983cited by this paper
• Pathological studies of human gastric cancer.

  1982cited by this paper
• Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

  1965cited by this paper
• The pathology and prognosis of gastric carcinoma.

  1960cited by this paper
• Geschwülste des Magens und Duodenums

  year unknowncited by this paper

• Molecular Insight into Gastric Cancer Invasion—Current Status and Future Directions

  2023cites this paper
• Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

  2022cites this paper
• Identification of hub pathways and drug candidates in gastric cancer through systems biology

  2022cites this paper
• Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer

  2022cites this paper
• TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR

  2022cites this paper
• A prognostic gene signature for gastric cancer and the immune infiltration-associated mechanism underlying the signature gene, PLG

  2022cites this paper
• Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.

  2020cites this paper
• Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

  2018cites this paper
• The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis

  2017cites this paper
• Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis

  2017cites this paper
• Impact of proteolytic enzymes in colorectal cancer development and progression.

  2014cites this paper
• Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

  2014cites this paper
• MECHANISMS OF TUMOR PROGRESSION

  2014cites this paper
• The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small cell lung cancer

  2013cites this paper
• Clinical significance of the uPA system in gastric cancer with peritoneal metastasis

  2013cites this paper
• Prognosis in adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia evaluated by uPAR‐immunohistochemistry

  2012cites this paper
• Clinical applications of the urokinase receptor (uPAR) for cancer patients.

  2011cites this paper
• Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

  2011cites this paper
• Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse‐type gastric cancer susceptibility

  2010cites this paper
• Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non‐small cell lung cancer

  2009cites this paper
• Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

  2008cites this paper
• Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers

  2008cites this paper
• The tumor marker and prognostic impact of cathepsin B , cathepsin L , urokinase-type plasminogen activator and its inhibitor type-1 in colorectal cancer

  2008cites this paper
• Matrix Metalloproteinase-9 Expression in the Normal Mucosa–Adenoma–Dysplasia–Adenocarcinoma Sequence of the Colon

  2008cites this paper
• Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells

  2008cites this paper
• Urokinase receptor variants in tissue and body fluids.

  2007cites this paper
• Inhibitors of proteases as anticancer drugs.

  2005cites this paper
• Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.

  2005cites this paper
• Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.

  2005cites this paper
• Inhibitors of proteases as anticancer drugs Minireview

  2005cites this paper
• Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer

  2004cites this paper
• Relationship between Urokinase-Type Plasminogen Receptor, Interleukin-8 Gene Expression and Clinicopathological Features in Gastric Cancer

  2004cites this paper
• Plasminogen Activator System Urokinase-typeof Gastric Cancer Cells by Up-Regulating the Macrophage Inhibitory Cytokine-1 Induces the Invasiveness

  2003cites this paper
• Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.

  2003cites this paper
• A New Approach to Phenotyping Disseminated Tumor Cells: Methodological advances and Clinical Implications

  2000cites this paper
• Urokinase receptor up‐regulation in head and neck squamous cell carcinoma

  2000cites this paper
• Proteases in gastrointestinal neoplastic diseases.

  2000cites this paper
• Changes of the Coagulation and Fibrinolysis System in Malignancy: Their possible Impact on Future Diagnostic and Therapeutic Procedures

  2000cites this paper
• Stress response genes: the genes that make cancer metastasize

  2000cites this paper
• Tissue urokinase-type plasminogen activator receptor levels in breast cancer.

  2000cites this paper
• The role of cysteine and serine proteases in colorectal carcinoma

  1999cites this paper
• Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.

  1999cites this paper
• The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer

  1999cites this paper
• Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).

  1998cites this paper
• Prognostic factors in a series of 297 patients with gastric adenocarcinoma undergoing surgical resection.

  1998cites this paper